Dr. Patricia Beckmann is the Entrepreneurial Program Coordinator and Grant Administrator for AZBio supporting the Economic Development Association’s Seed Fund Grant at AZBio. Patricia’s overall career spans research, operations, law and venture capital.
The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Each unit is capable of analyzing hundreds of samples per day.Continue reading
- Adaptive Extends Immune Medicine Platform to Discover Therapeutic Antibodies From Recovered COVID-19 Patients
- Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilities
- Companies Will Begin Work Immediately
Point-of-care blood test detects evidence of present or past exposure in 15 minutesContinue reading
TGen is stepping up through the untiring efforts of scientists and staff at TGen’s Pathogen and Microbiome Division (TGen North). The amazing group has a history of tracking the cause and source of disease outbreaks, antibiotic resistance, healthcare-acquired infections, microbial evolution, pathogen dispersal, and emerging infections. Continue reading
Have Questions about how the first COVID-19 Vaccine to go into clinical trials is being created. Listen to the I Am BIO Podcast where the CEO explains how it is being done.
PHOENIX — Governor Doug Ducey and Superintendent of Public Instruction Kathy Hoffman today announced the extension of Arizona school closures through the end of the school year. The extension follows updated guidance from the Centers for Disease Control and Prevention (CDC) and an announcement from the White House extending physical distancing guidelines until April 30, 2020. Continue reading
AZBio Members have access to substantial VWR discounts via the BIO Business Solutions®
Alex Gorsky, chairman and CEO of Johnson & Johnson, one of several companies that’s developed a potential coronavirus vaccine, tells TODAY that his company has a candidate “that has a high degree of probability of being successful.” He anticipates starting tests in humans in September and says “We could have vaccines ready in Q1 and Q2 of 2021.” (Source: TODAY Show)Continue reading